BETA


2018/0118(NLE) Subjecting the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures

Progress: Awaiting final decision

RoleCommitteeRapporteurShadows
Lead LIBE ŠKRIPEK Branislav (icon: ECR ECR) HORTEFEUX Brice (icon: PPE PPE), HEDH Anna (icon: S&D S&D), PAGAZAURTUNDÚA Maite (icon: ALDE ALDE), ANDERSON Martina (icon: GUE/NGL GUE/NGL)
Lead committee dossier:

Events

2018/09/11
   EP - Results of vote in Parliament
2018/09/11
   EP - Decision by Parliament, 1st reading/single reading
Details

The European Parliament adopted by 635 votes to 11, with 37 abstentions, following the consultation procedure, a legislative resolution on the draft Council implementing decision on subjecting the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenylN-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures.

Parliament approved the Council draft which aims to subject the new psychoactive substances cyclopropylfentanyl and methoxyacetylfentanyl to control measures and criminal penalties, as provided for under their legislation, in compliance with their obligations under the 1961 United Nations Single Convention on Narcotic Drugs as amended by the 1972 Protocol.

Documents
2018/09/03
   EP - Committee report tabled for plenary, 1st reading/single reading
Details

The Committee on Civil Liberties, Justice and Home Affairs adopted the report by Branislav ŠKRIPEK (ECR, SK) on the draft Council implementing decision on subjecting the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenylN-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures.

The committee recommended that Parliament approve the Council draft .

The risks of cyclopropylfentanyl and methoxyacetylfentanyl were assessed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and submitted to the Commission and to the Council on 23 March 2018.

The available evidence and information on the health and social risks that the substances pose, given also their similarities with fentanyl, provides sufficient ground for subjecting cyclopropylfentanyl and methoxyacetylfentanyl to control measures across the Union.

Documents
2018/08/30
   EP - Vote in committee, 1st reading/single reading
2018/07/02
   EP - Committee referral announced in Parliament, 1st reading/single reading
2018/06/21
   EP - Committee draft report
Documents
2018/06/20
   EP - Responsible Committee
2018/06/11
   EC - Legislative proposal published
Details

PURPOSE: to subject the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures.

PROPOSED ACT: Council Implementing Decision.

ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.

BACKGROUND: the risks of cyclopropylfentanyl and methoxyacetylfentanyl were assessed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and submitted to the Commission and to the Council on 23 March 2018.

They are both synthetic opioids and are structurally related to fentanyl, a controlled substance widely used in medicine as an adjunct to general anaesthesia during surgery and for pain management. The acute toxicity of cyclopropylfentanyl and methoxyacetylfentanyl are such that it can cause severe harms to the health of individuals.

Cyclopropylfentanyl has been available in the Union since at least June 2017 and has been detected in six Member States who reported 140 seizures in total between June 2017 and January 2018. 77 deaths have been reported by two Member States where exposure to cyclopropylfentanyl was confirmed.

Methoxyacetylfentanyl has been available in the Union since at least November 2016 and has been detected in eleven Member States who reported 44 seizures in total between June and December 2017. 13 deaths have been reported by four Member States where exposure to methoxyacetylfentanyl was confirmed.

Both cyclopropylfentanyl and methoxyacetylfentanyl appear to be sold online in small and wholesale amounts, under the guise of a "research chemical" or as "legal" replacement to illicit opioids, mainly as a powder or as a solution in ready-to-use nasal sprays.

The available evidence and information on the health and social risks that the substances pose, given also their similarities with fentanyl, provides sufficient ground for subjecting cyclopropylfentanyl and methoxyacetylfentanyl to control measures across the Union.

CONTENT: the draft Council implementing decision aims to subject the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide ('cyclopropylfentanyl') and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide ('methoxyacetylfentanyl') to control measures and criminal penalties, as provided for under their legislation, in compliance with their obligations under the 1961 United Nations Single Convention on Narcotic Drugs as amended by the 1972 Protocol.

Documents
2018/04/30
   EC - Initial legislative proposal published
Details

PURPOSE: to subject the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures.

PROPOSED ACT: Council Implementing Decision.

ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.

BACKGROUND: the risks of cyclopropylfentanyl and methoxyacetylfentanyl were assessed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and submitted to the Commission and to the Council on 23 March 2018.

They are both synthetic opioids and are structurally related to fentanyl, a controlled substance widely used in medicine as an adjunct to general anaesthesia during surgery and for pain management. The acute toxicity of cyclopropylfentanyl and methoxyacetylfentanyl are such that it can cause severe harms to the health of individuals.

Cyclopropylfentanyl has been available in the Union since at least June 2017 and has been detected in six Member States who reported 140 seizures in total between June 2017 and January 2018. 77 deaths have been reported by two Member States where exposure to cyclopropylfentanyl was confirmed.

Methoxyacetylfentanyl has been available in the Union since at least November 2016 and has been detected in eleven Member States who reported 44 seizures in total between June and December 2017. 13 deaths have been reported by four Member States where exposure to methoxyacetylfentanyl was confirmed.

Both cyclopropylfentanyl and methoxyacetylfentanyl appear to be sold online in small and wholesale amounts, under the guise of a "research chemical" or as "legal" replacement to illicit opioids, mainly as a powder or as a solution in ready-to-use nasal sprays.

The available evidence and information on the health and social risks that the substances pose, given also their similarities with fentanyl, provides sufficient ground for subjecting cyclopropylfentanyl and methoxyacetylfentanyl to control measures across the Union.

CONTENT: the draft Council decision aims to subject the new psychoactive substances cyclopropylfentanyl and methoxyacetylfentanyl) to control measures and criminal penalties, as provided for under their legislation, in compliance with their obligations under the 1961 United Nations Single Convention on Narcotic Drugs as amended by the 1972 Protocol.

Documents

Votes

A8-0271/2018 - Branislav Škripek - Vote unique 11/09/2018 12:43:06.000

2018/09/11 Outcome: +: 635, 0: 37, -: 11
DE FR IT ES PL GB RO CZ BE HU PT AT SE NL EL BG SK FI DK HR LT SI EE IE CY MT LU LV ??
Total
85
65
64
49
51
67
28
21
20
20
18
18
18
25
17
15
13
12
11
10
9
8
6
8
6
6
5
5
2
icon: PPE PPE
202

United Kingdom PPE

2

Finland PPE

2

Denmark PPE

For (1)

1

Estonia PPE

For (1)

1

Cyprus PPE

1

Luxembourg PPE

2
icon: S&D S&D
172

Netherlands S&D

For (2)

2

Croatia S&D

2

Lithuania S&D

1

Slovenia S&D

For (1)

1

Estonia S&D

For (1)

1

Ireland S&D

For (1)

1

Cyprus S&D

2

Malta S&D

3

Luxembourg S&D

For (1)

1

Latvia S&D

1
icon: ALDE ALDE
63

Germany ALDE

3

United Kingdom ALDE

1

Romania ALDE

3

Portugal ALDE

1

Austria ALDE

For (1)

1

Sweden ALDE

2

Denmark ALDE

2

Croatia ALDE

2

Slovenia ALDE

For (1)

1

Estonia ALDE

3

Ireland ALDE

For (1)

1

Luxembourg ALDE

For (1)

1

Latvia ALDE

1
icon: ECR ECR
70

Italy ECR

2

Romania ECR

2

Czechia ECR

2

Sweden ECR

2

Netherlands ECR

2

Greece ECR

For (1)

1

Bulgaria ECR

2
2

Croatia ECR

For (1)

1

Lithuania ECR

1

Cyprus ECR

1
icon: Verts/ALE Verts/ALE
45

France Verts/ALE

4

Italy Verts/ALE

For (1)

1

Spain Verts/ALE

2

United Kingdom Verts/ALE

5

Belgium Verts/ALE

2

Hungary Verts/ALE

2

Austria Verts/ALE

3

Netherlands Verts/ALE

2

Finland Verts/ALE

For (1)

1

Denmark Verts/ALE

For (1)

1

Croatia Verts/ALE

For (1)

1

Lithuania Verts/ALE

For (1)

1

Slovenia Verts/ALE

For (1)

1

Estonia Verts/ALE

For (1)

1

Luxembourg Verts/ALE

For (1)

1
icon: GUE/NGL GUE/NGL
43

Italy GUE/NGL

2

United Kingdom GUE/NGL

1

Sweden GUE/NGL

For (1)

1

Netherlands GUE/NGL

3

Finland GUE/NGL

For (1)

1

Denmark GUE/NGL

For (1)

1

Ireland GUE/NGL

For (1)

Against (1)

2

Cyprus GUE/NGL

2
icon: ENF ENF
31

Germany ENF

Abstain (1)

1

Poland ENF

2

Belgium ENF

For (1)

1

Netherlands ENF

4
icon: EFDD EFDD
37

Germany EFDD

Abstain (1)

1

Poland EFDD

1

Czechia EFDD

Abstain (1)

1

EFDD

Abstain (1)

1
icon: NI NI
19

Germany NI

Against (1)

2

France NI

For (1)

1

United Kingdom NI

Against (1)

4

NI

For (1)

1

History

(these mark the time of scraping, not the official date of the change)

events/5
date
2018-09-11T00:00:00
type
Results of vote in Parliament
body
EP
docs
  • url
    https://oeil.secure.europarl.europa.eu/oeil/popups/sda.do?id=31453&l=en
    title
    Results of vote in Parliament
activities
  • date
    2018-04-30T00:00:00
    docs
    • url
      http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2018/0253/COM_COM(2018)0253_EN.pdf
      text
      • PURPOSE: to subject the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures.

        PROPOSED ACT: Council Implementing Decision.

        ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.

        BACKGROUND: the risks of cyclopropylfentanyl and methoxyacetylfentanyl were assessed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and submitted to the Commission and to the Council on 23 March 2018.

        They are both synthetic opioids and are structurally related to fentanyl, a controlled substance widely used in medicine as an adjunct to general anaesthesia during surgery and for pain management. The acute toxicity of cyclopropylfentanyl and methoxyacetylfentanyl are such that it can cause severe harms to the health of individuals.

        Cyclopropylfentanyl has been available in the Union since at least June 2017 and has been detected in six Member States who reported 140 seizures in total between June 2017 and January 2018. 77 deaths have been reported by two Member States where exposure to cyclopropylfentanyl was confirmed.

        Methoxyacetylfentanyl has been available in the Union since at least November 2016 and has been detected in eleven Member States who reported 44 seizures in total between June and December 2017. 13 deaths have been reported by four Member States where exposure to methoxyacetylfentanyl was confirmed.

        Both cyclopropylfentanyl and methoxyacetylfentanyl appear to be sold online in small and wholesale amounts, under the guise of a "research chemical" or as "legal" replacement to illicit opioids, mainly as a powder or as a solution in ready-to-use nasal sprays.

        The available evidence and information on the health and social risks that the substances pose, given also their similarities with fentanyl, provides sufficient ground for subjecting cyclopropylfentanyl and methoxyacetylfentanyl to control measures across the Union.

        CONTENT: the draft Council decision aims to subject the new psychoactive substances cyclopropylfentanyl and methoxyacetylfentanyl) to control measures and criminal penalties, as provided for under their legislation, in compliance with their obligations under the 1961 United Nations Single Convention on Narcotic Drugs as amended by the 1972 Protocol.

      title
      COM(2018)0253
      type
      Initial legislative proposal published
      celexid
      CELEX:52018PC0253:EN
    body
    EC
    commission
    • DG
      Commissioner
      AVRAMOPOULOS Dimitris
    type
    Initial legislative proposal published
  • date
    2018-06-11T00:00:00
    docs
    • url
      http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=9420%2F18&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
      text
      • PURPOSE: to subject the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures.

        PROPOSED ACT: Council Implementing Decision.

        ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.

        BACKGROUND: the risks of cyclopropylfentanyl and methoxyacetylfentanyl were assessed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and submitted to the Commission and to the Council on 23 March 2018.

        They are both synthetic opioids and are structurally related to fentanyl, a controlled substance widely used in medicine as an adjunct to general anaesthesia during surgery and for pain management. The acute toxicity of cyclopropylfentanyl and methoxyacetylfentanyl are such that it can cause severe harms to the health of individuals.

        Cyclopropylfentanyl has been available in the Union since at least June 2017 and has been detected in six Member States who reported 140 seizures in total between June 2017 and January 2018. 77 deaths have been reported by two Member States where exposure to cyclopropylfentanyl was confirmed.

        Methoxyacetylfentanyl has been available in the Union since at least November 2016 and has been detected in eleven Member States who reported 44 seizures in total between June and December 2017. 13 deaths have been reported by four Member States where exposure to methoxyacetylfentanyl was confirmed.

        Both cyclopropylfentanyl and methoxyacetylfentanyl appear to be sold online in small and wholesale amounts, under the guise of a "research chemical" or as "legal" replacement to illicit opioids, mainly as a powder or as a solution in ready-to-use nasal sprays.

        The available evidence and information on the health and social risks that the substances pose, given also their similarities with fentanyl, provides sufficient ground for subjecting cyclopropylfentanyl and methoxyacetylfentanyl to control measures across the Union.

        CONTENT: the draft Council implementing decision aims to subject the new psychoactive substances  N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide ('cyclopropylfentanyl') and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide ('methoxyacetylfentanyl') to control measures and criminal penalties, as provided for under their legislation, in compliance with their obligations under the 1961 United Nations Single Convention on Narcotic Drugs as amended by the 1972 Protocol.

      type
      Legislative proposal published
      title
      09420/2018
    body
    EC
    commission
    • DG
      Commissioner
      AVRAMOPOULOS Dimitris
    type
    Legislative proposal published
  • date
    2018-07-02T00:00:00
    body
    EP
    type
    Committee referral announced in Parliament, 1st reading/single reading
    committees
    • body
      EP
      shadows
      responsible
      True
      committee
      LIBE
      date
      2018-06-20T00:00:00
      committee_full
      Civil Liberties, Justice and Home Affairs
      rapporteur
      • group
        ECR
        name
        ŠKRIPEK Branislav
  • date
    2018-08-30T00:00:00
    body
    EP
    type
    Vote in committee, 1st reading/single reading
    committees
    • body
      EP
      shadows
      responsible
      True
      committee
      LIBE
      date
      2018-06-20T00:00:00
      committee_full
      Civil Liberties, Justice and Home Affairs
      rapporteur
      • group
        ECR
        name
        ŠKRIPEK Branislav
  • body
    EP
    docs
    • url
      http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2018-0271&language=EN
      text
      • The Committee on Civil Liberties, Justice and Home Affairs adopted the report by Branislav ŠKRIPEK (ECR, SK) on the draft Council implementing decision on subjecting the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenylN-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures.

        The committee recommended that Parliament approve the Council draft.

        The risks of cyclopropylfentanyl and methoxyacetylfentanyl were assessed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and submitted to the Commission and to the Council on 23 March 2018.

        The available evidence and information on the health and social risks that the substances pose, given also their similarities with fentanyl, provides sufficient ground for subjecting cyclopropylfentanyl and methoxyacetylfentanyl to control measures across the Union.

      type
      Committee report tabled for plenary, 1st reading/single reading
      title
      A8-0271/2018
    type
    Committee report tabled for plenary, 1st reading/single reading
    committees
    • body
      EP
      shadows
      responsible
      True
      committee
      LIBE
      date
      2018-06-20T00:00:00
      committee_full
      Civil Liberties, Justice and Home Affairs
      rapporteur
      • group
        ECR
        name
        ŠKRIPEK Branislav
    date
    2018-09-03T00:00:00
  • date
    2018-09-11T00:00:00
    body
    EP
    type
    Vote in plenary scheduled
commission
  • body
    EC
    dg
    Migration and Home Affairs
    commissioner
    AVRAMOPOULOS Dimitris
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Civil Liberties, Justice and Home Affairs
committee
LIBE
date
  • 2018-06-20T00:00:00
rapporteur
  • name
    ŠKRIPEK Branislav
    group
    European Conservatives and Reformists
    abbr
    ECR
shadows
committees/0
body
EP
shadows
responsible
True
committee
LIBE
date
2018-06-20T00:00:00
committee_full
Civil Liberties, Justice and Home Affairs
rapporteur
  • group
    ECR
    name
    ŠKRIPEK Branislav
docs
  • date
    2018-06-21T00:00:00
    docs
    • url
      http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.813
      title
      PE623.813
    type
    Committee draft report
    body
    EP
events
  • date
    2018-04-30T00:00:00
    type
    Initial legislative proposal published
    body
    EC
    docs
    summary
  • date
    2018-06-11T00:00:00
    type
    Legislative proposal published
    body
    EC
    docs
    • url
      http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=9420%2F18&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
      title
      09420/2018
    summary
  • date
    2018-07-02T00:00:00
    type
    Committee referral announced in Parliament, 1st reading/single reading
    body
    EP
  • date
    2018-08-30T00:00:00
    type
    Vote in committee, 1st reading/single reading
    body
    EP
  • date
    2018-09-03T00:00:00
    type
    Committee report tabled for plenary, 1st reading/single reading
    body
    EP
    docs
    • url
      http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2018-0271&language=EN
      title
      A8-0271/2018
    summary
  • date
    2018-09-11T00:00:00
    type
    Decision by Parliament, 1st reading/single reading
    body
    EP
    docs
    • url
      http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2018-0320
      title
      T8-0320/2018
    summary
links
other
  • body
    EC
    dg
    commissioner
    AVRAMOPOULOS Dimitris
procedure/Modified legal basis
Old
Rules of Procedure EP 150
New
Rules of Procedure EP 159
procedure/dossier_of_the_committee
Old
LIBE/8/13013
New
  • LIBE/8/13013
procedure/instrument
Decision
procedure/stage_reached
Old
Awaiting Parliament 1st reading / single reading / budget 1st stage
New
Awaiting final decision
procedure/subject
Old
  • 7.30.30.04 Action to combat drugs and drug-trafficking
New
7.30.30.04
Action to combat drugs and drug-trafficking
activities/0/docs/0/text
  • PURPOSE: to subject the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures.

    PROPOSED ACT: Council Implementing Decision.

    ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.

    BACKGROUND: the risks of cyclopropylfentanyl and methoxyacetylfentanyl were assessed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and submitted to the Commission and to the Council on 23 March 2018.

    They are both synthetic opioids and are structurally related to fentanyl, a controlled substance widely used in medicine as an adjunct to general anaesthesia during surgery and for pain management. The acute toxicity of cyclopropylfentanyl and methoxyacetylfentanyl are such that it can cause severe harms to the health of individuals.

    Cyclopropylfentanyl has been available in the Union since at least June 2017 and has been detected in six Member States who reported 140 seizures in total between June 2017 and January 2018. 77 deaths have been reported by two Member States where exposure to cyclopropylfentanyl was confirmed.

    Methoxyacetylfentanyl has been available in the Union since at least November 2016 and has been detected in eleven Member States who reported 44 seizures in total between June and December 2017. 13 deaths have been reported by four Member States where exposure to methoxyacetylfentanyl was confirmed.

    Both cyclopropylfentanyl and methoxyacetylfentanyl appear to be sold online in small and wholesale amounts, under the guise of a "research chemical" or as "legal" replacement to illicit opioids, mainly as a powder or as a solution in ready-to-use nasal sprays.

    The available evidence and information on the health and social risks that the substances pose, given also their similarities with fentanyl, provides sufficient ground for subjecting cyclopropylfentanyl and methoxyacetylfentanyl to control measures across the Union.

    CONTENT: the draft Council decision aims to subject the new psychoactive substances cyclopropylfentanyl and methoxyacetylfentanyl) to control measures and criminal penalties, as provided for under their legislation, in compliance with their obligations under the 1961 United Nations Single Convention on Narcotic Drugs as amended by the 1972 Protocol.

activities/0/docs/0/type
Old
Legislative proposal published
New
Initial legislative proposal published
activities/0/type
Old
Legislative proposal published
New
Initial legislative proposal published
activities/1
date
2018-06-11T00:00:00
docs
  • url
    http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=9420%2F18&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC
    text
    • PURPOSE: to subject the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures.

      PROPOSED ACT: Council Implementing Decision.

      ROLE OF THE EUROPEAN PARLIAMENT: the Council adopts the act after consulting the European Parliament but without being obliged to follow its opinion.

      BACKGROUND: the risks of cyclopropylfentanyl and methoxyacetylfentanyl were assessed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and submitted to the Commission and to the Council on 23 March 2018.

      They are both synthetic opioids and are structurally related to fentanyl, a controlled substance widely used in medicine as an adjunct to general anaesthesia during surgery and for pain management. The acute toxicity of cyclopropylfentanyl and methoxyacetylfentanyl are such that it can cause severe harms to the health of individuals.

      Cyclopropylfentanyl has been available in the Union since at least June 2017 and has been detected in six Member States who reported 140 seizures in total between June 2017 and January 2018. 77 deaths have been reported by two Member States where exposure to cyclopropylfentanyl was confirmed.

      Methoxyacetylfentanyl has been available in the Union since at least November 2016 and has been detected in eleven Member States who reported 44 seizures in total between June and December 2017. 13 deaths have been reported by four Member States where exposure to methoxyacetylfentanyl was confirmed.

      Both cyclopropylfentanyl and methoxyacetylfentanyl appear to be sold online in small and wholesale amounts, under the guise of a "research chemical" or as "legal" replacement to illicit opioids, mainly as a powder or as a solution in ready-to-use nasal sprays.

      The available evidence and information on the health and social risks that the substances pose, given also their similarities with fentanyl, provides sufficient ground for subjecting cyclopropylfentanyl and methoxyacetylfentanyl to control measures across the Union.

      CONTENT: the draft Council implementing decision aims to subject the new psychoactive substances  N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide ('cyclopropylfentanyl') and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide ('methoxyacetylfentanyl') to control measures and criminal penalties, as provided for under their legislation, in compliance with their obligations under the 1961 United Nations Single Convention on Narcotic Drugs as amended by the 1972 Protocol.

    type
    Legislative proposal published
    title
    09420/2018
type
Legislative proposal published
body
EC
commission
  • DG
    Commissioner
    AVRAMOPOULOS Dimitris
activities/2
date
2018-07-02T00:00:00
body
EP
type
Committee referral announced in Parliament, 1st reading/single reading
committees
  • body
    EP
    shadows
    responsible
    True
    committee
    LIBE
    date
    2018-06-20T00:00:00
    committee_full
    Civil Liberties, Justice and Home Affairs
    rapporteur
    • group
      ECR
      name
      ŠKRIPEK Branislav
activities/3
date
2018-08-30T00:00:00
body
EP
type
Vote in committee, 1st reading/single reading
committees
  • body
    EP
    shadows
    responsible
    True
    committee
    LIBE
    date
    2018-06-20T00:00:00
    committee_full
    Civil Liberties, Justice and Home Affairs
    rapporteur
    • group
      ECR
      name
      ŠKRIPEK Branislav
activities/4
body
EP
docs
  • url
    http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2018-0271&language=EN
    text
    • The Committee on Civil Liberties, Justice and Home Affairs adopted the report by Branislav ŠKRIPEK (ECR, SK) on the draft Council implementing decision on subjecting the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenylN-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures.

      The committee recommended that Parliament approve the Council draft.

      The risks of cyclopropylfentanyl and methoxyacetylfentanyl were assessed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and submitted to the Commission and to the Council on 23 March 2018.

      The available evidence and information on the health and social risks that the substances pose, given also their similarities with fentanyl, provides sufficient ground for subjecting cyclopropylfentanyl and methoxyacetylfentanyl to control measures across the Union.

    type
    Committee report tabled for plenary, 1st reading/single reading
    title
    A8-0271/2018
type
Committee report tabled for plenary, 1st reading/single reading
committees
  • body
    EP
    shadows
    responsible
    True
    committee
    LIBE
    date
    2018-06-20T00:00:00
    committee_full
    Civil Liberties, Justice and Home Affairs
    rapporteur
    • group
      ECR
      name
      ŠKRIPEK Branislav
date
2018-09-03T00:00:00
activities/5
date
2018-09-11T00:00:00
body
EP
type
Vote in plenary scheduled
committees/0/date
2018-06-20T00:00:00
committees/0/rapporteur
  • group
    ECR
    name
    ŠKRIPEK Branislav
committees/0/shadows
  • group
    EPP
    name
    HORTEFEUX Brice
  • group
    S&D
    name
    HEDH Anna
  • group
    ALDE
    name
    PAGAZAURTUNDÚA RUIZ Maite
  • group
    GUE/NGL
    name
    ANDERSON Martina
procedure/Modified legal basis
Rules of Procedure EP 150
procedure/dossier_of_the_committee
LIBE/8/13013
procedure/stage_reached
Old
Preparatory phase in Parliament
New
Awaiting Parliament 1st reading / single reading / budget 1st stage
activities
  • date
    2018-04-30T00:00:00
    docs
    • url
      http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2018/0253/COM_COM(2018)0253_EN.pdf
      celexid
      CELEX:52018PC0253:EN
      type
      Legislative proposal published
      title
      COM(2018)0253
    type
    Legislative proposal published
    body
    EC
    commission
    • DG
      Commissioner
      AVRAMOPOULOS Dimitris
committees
  • body
    EP
    responsible
    True
    committee_full
    Civil Liberties, Justice and Home Affairs
    committee
    LIBE
links
other
  • body
    EC
    dg
    commissioner
    AVRAMOPOULOS Dimitris
procedure
reference
2018/0118(NLE)
title
Subjecting the new psychoactive substances N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) to control measures
stage_reached
Preparatory phase in Parliament
subtype
Consultation of Parliament
type
NLE - Non-legislative enactments
subject
  • 7.30.30.04 Action to combat drugs and drug-trafficking